ClinicalTrials.gg
RecruitingNCT07944170NEU 02-25Updated Nov 18, 2026

Retinal Morpho-functional Evaluation of Patients Affected by Inherited Retinal Dystrophies

An observational study in Inherited Retinal Dystrophies, Retinitis Pigmentosa (RP) and Stargardt Disease, sponsored by Fondazione G.B. Bietti, IRCCS. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Fondazione G.B. Bietti, IRCCS · Observational

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
18
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 15 studies in Retinitis Pigmentosa with a site in Italy — 4 open to participants now, 7 under way, 1 of them phase 3. Retinitis Pigmentosa · Italy.

Started
2025
the only one that year
Observational
6 of 15
4 open now
Registered
15th of 15
by date
Lead sponsor
1 of 15
Fondazione G.B. Bietti, IRCCS

Among the 15 studies in Retinitis Pigmentosa with a site in Italy, this one is the only one that started in 2025, is one of 6 observational ones, and was the 15th registered.

Retinitis Pigmentosa

281 studies on the registry are indexed under Retinitis Pigmentosa; 74 are open to participants now.

Browse Retinitis Pigmentosa studies →

Open to participants now

4 of the 15 studies in Retinitis Pigmentosa with a site in Italy are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 49 Retinitis Pigmentosa studies recruiting now, 37 (76%) set no upper age limit and 6 (12%) stop at 75 or younger; 16 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Retinitis Pigmentosa with a site in Italy, or all of them as a file.
02

Study summary

The present study aims to perform a detailed morpho-anatomical and electro-functional characterization of patients affected by IRD, to investigate on the features of specific retinal layers (outer and inner) and to identify the functional involvement of macular elements located in specific areas. Through a systematic approach to anatomical and functional pattern classifications, this study seeks to refine the phenotypic understanding of IRD and to contribute to a deeper comprehension of its pathophysiological underpinnings, for exploring whether subretinal factors are involving in the etiopathogenesis.

Read the detailed description

This single-center retrospective observational study evaluates retinal structure and function in patients with clinically confirmed inherited retinal dystrophies. Patients are identified consecutively from those evaluated between 2015 and August 31, 2025. After written informed consent is obtained, demographic and clinical data are extracted from existing records, together with results from a single previously completed ophthalmic visit (Visit 1). The data include medical history, best-corrected visual acuity, anterior and posterior segment examination, intraocular pressure, spectral-domain optical coherence tomography, optical coherence tomography angiography, multifocal electroretinography, multifocal photopic negative response recordings, visual field testing, and documented ocular complications related to inherited retinal dystrophies.

03

Conditions studied

  • Inherited Retinal Dystrophies
  • Retinitis Pigmentosa (RP)
  • Stargardt Disease
  • Cone Rod Dystrophy
  • Rod Dystrophy
  • Cone Dystrophy

Keywords

  • inherited retinal dystrophies
  • Multifocal Electroretinogram
  • Multifocal Photopic Negative Response
  • Spectral Domain-Optical Coherence Tomography
  • Optical Coherence Tomography-Angiography
  • Best Correct Visual Acuity
  • Central Retinal Thickness
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients aged 18 to 90 years with clinically confirmed inherited retinal dystrophies who were evaluated at the study center between 2015 and August 31, 2025, and have the clinical and instrumental records required by the protocol.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with clinically confirmed inherited retinal dystrophy
  • Age between 18 and 90 years
  • Male or female patients
  • Available recordings of mfERG and mfPhNR, SD-OCT and OCT-A, Visual Acuity (BCVA) and Visual Field (VF)
  • Phakic and pseudophakic eyes
  • freely granted and acquired before data collection

Exclusion criteria

Exclusion Criteria:

  • Patients underwent cataract surgery 6 months before data acquisition
  • Patients with any other ophthalmological diseases affecting cornea, lens, optic nerve and acquired retinal diseases (i.e. central serous chorioretinopathy, retinal vein occlusion, age-related macular degeneration) at the time of data acquisition
  • Patients with diabetes and\or any other systemic condition affecting the macular function and structure
  • Patients who underwent to macular laser procedures before data acquisition
  • Concomitant treatment with any systemic or ocular drug influencing macular structure and function at the time of data acquisition
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
18 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with inherited retinal dystrophies

    Patients with clinically confirmed inherited retinal dystrophies identified consecutively from those evaluated at the study center between 2015 and August 31, 2025

06

What researchers measure

Primary outcomes

  1. Central Retinal Thickness Measured by SD-OCT

    Central retinal thickness, in micrometers (µm), measured by spectral-domain optical coherence tomography (SD-OCT).

    Time frame: At a single previously completed ophthalmic visit (Visit 1).

  2. Ring 1 Response Amplitude Density Measured by Multifocal Electroretinography

    Response amplitude density, in nV/deg², measured by multifocal electroretinography (mfERG) in the innermost fovea-centered ring (R1).

    Time frame: At a single previously completed ophthalmic visit (Visit 1).

Secondary outcomes

  1. Best-Corrected Visual Acuity

    Mean best-corrected visual acuity, expressed in logMAR.

    Time frame: At a single previously completed ophthalmic visit (Visit 1).

  2. Multifocal Electroretinography Response Amplitude Density by Macular Ring

    Response amplitude density, in nV/deg², measured by multifocal electroretinography (mfERG) and reported separately for the five fovea-centered rings (R1-R5).

    Time frame: At a single previously completed ophthalmic visit (Visit 1).

  3. Multifocal Photopic Negative Response Amplitude Density by Macular Ring

    Response amplitude density, in nV/deg², measured from multifocal photopic negative response (mfPhNR) recordings and reported separately for the five fovea-centered rings (R1-R5).

    Time frame: At a single previously completed ophthalmic visit (Visit 1).

  4. Mean Perimetric Sensitivity

    Mean perimetric sensitivity derived from visual field testing.

    Time frame: At a single previously completed ophthalmic visit (Visit 1).

  5. Inner and Outer Retinal Layer Thickness by Macular Region

    Thickness of the inner and outer retinal layers, in micrometers (µm), measured by SD-OCT in localized macular regions defined by the Early Treatment Diabetic Retinopathy Study (ETDRS) map.

    Time frame: At a single previously completed ophthalmic visit (Visit 1).

  6. Macular Vessel Density Measured by OCT Angiography

    Vessel density measured by optical coherence tomography angiography (OCT-A) in localized macular regions and reported separately for the superficial capillary plexus, deep capillary plexus, and choriocapillaris.

    Time frame: At a single previously completed ophthalmic visit (Visit 1).

  7. Inherited Retinal Dystrophy-Related Ocular Complications

    Ocular complications documented in patients with inherited retinal dystrophies, including macular edema and cataract.

    Time frame: At a single previously completed ophthalmic visit (Visit 1).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Grover S, Murthy RK, Brar VS, Chalam KV. Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (spectralis). Am J Ophthalmol. 2009 Aug;148(2):266-71. doi: 10.1016/j.ajo.2009.03.006. Epub 2009 May 9. PubMed 19427616 ↗
  • Ziccardi L, Barbano L, Boffa L, Albanese M, Nicoletti CG, Landi D, Grzybowski A, Falsini B, Marfia GA, Centonze D, Parisi V. Functional Assessment of Outer and Middle Macular Layers in Multiple Sclerosis. J Clin Med. 2020 Nov 22;9(11):3766. doi: 10.3390/jcm9113766. PubMed 33266435 ↗
  • Antonelli G, Parravano M, Barbano L, Costanzo E, Bertelli M, Medori MC, Parisi V, Ziccardi L. Multimodal Study of PRPH2 Gene-Related Retinal Phenotypes. Diagnostics (Basel). 2022 Jul 31;12(8):1851. doi: 10.3390/diagnostics12081851. PubMed 36010202 ↗
  • Ziccardi L, Barbano L, D'Andrea M, Bruselles A, Dell'Aquila C, Niceta M, Mancini C, Leone A, Carvetta M, Albanese M, Stellacci E, Tartaglia M, Cordeddu V. Variable Ophthalmologic Phenotypes Associated with Biallelic Loss-of-Function Variants in POMGNT1. Int J Mol Sci. 2025 Apr 1;26(7):3278. doi: 10.3390/ijms26073278. PubMed 40244109 ↗
  • Arrigo A, Aragona E, Perra C, Saladino A, Amato A, Bianco L, Pina A, Basile G, Bandello F, Battaglia Parodi M. Morphological and functional involvement of the inner retina in retinitis pigmentosa. Eye (Lond). 2023 May;37(7):1424-1431. doi: 10.1038/s41433-022-02139-7. Epub 2022 Jun 29. PubMed 35768721 ↗
  • Falsini B, Placidi G, De Siena E, Savastano MC, Minnella AM, Maceroni M, Midena G, Ziccardi L, Parisi V, Bertelli M, Maltese PE, Chiurazzi P, Rizzo S. USH2A-Related Retinitis Pigmentosa: Staging of Disease Severity and Morpho-Functional Studies. Diagnostics (Basel). 2021 Feb 1;11(2):213. doi: 10.3390/diagnostics11020213. PubMed 33535592 ↗
  • Barbano L, Antonelli G, Parravano M, Costanzo E, Parisi V, Ziccardi L. Middle-Inner Macular Layers Dysfunction in a Case of Stellate Foveomacular Retinoschisis Detected by Abnormal Multifocal Photopic Negative Response Recordings. Diagnostics (Basel). 2022 Nov 10;12(11):2753. doi: 10.3390/diagnostics12112753. PubMed 36359596 ↗
  • Haraguchi Y, Chiang TK, Yu M. Application of Electrophysiology in Non-Macular Inherited Retinal Dystrophies. J Clin Med. 2023 Nov 6;12(21):6953. doi: 10.3390/jcm12216953. PubMed 37959417 ↗
  • Ziccardi L, Giannini D, Lombardo G, Serrao S, Dell'Omo R, Nicoletti A, Bertelli M, Lombardo M. Multimodal Approach to Monitoring and Investigating Cone Structure and Function in an Inherited Macular Dystrophy. Am J Ophthalmol. 2015 Aug;160(2):301-312.e6. doi: 10.1016/j.ajo.2015.04.024. Epub 2015 Apr 20. PubMed 25908487 ↗
  • Gomez-Benlloch A, Garrell-Salat X, Cobos E, Lopez E, Esteve-Garcia A, Ruiz S, Vazquez M, Sararols L, Biarnes M. Optical Coherence Tomography in Inherited Macular Dystrophies: A Review. Diagnostics (Basel). 2024 Apr 24;14(9):878. doi: 10.3390/diagnostics14090878. PubMed 38732293 ↗
  • Daich Varela M, Esener B, Hashem SA, Cabral de Guimaraes TA, Georgiou M, Michaelides M. Structural evaluation in inherited retinal diseases. Br J Ophthalmol. 2021 Dec;105(12):1623-1631. doi: 10.1136/bjophthalmol-2021-319228. Epub 2021 May 12. PubMed 33980508 ↗
  • Arrigo A, Romano F, Albertini G, Aragona E, Bandello F, Battaglia Parodi M. Vascular Patterns in Retinitis Pigmentosa on Swept-Source Optical Coherence Tomography Angiography. J Clin Med. 2019 Sep 10;8(9):1425. doi: 10.3390/jcm8091425. PubMed 31510025 ↗
  • Battaglia Parodi M, Cicinelli MV, Rabiolo A, Pierro L, Gagliardi M, Bolognesi G, Bandello F. Vessel density analysis in patients with retinitis pigmentosa by means of optical coherence tomography angiography. Br J Ophthalmol. 2017 Apr;101(4):428-432. doi: 10.1136/bjophthalmol-2016-308925. Epub 2016 Jun 24. PubMed 27343210 ↗
  • Yang YJ, Peng J, Ying D, Peng QH. A Brief Review on the Pathological Role of Decreased Blood Flow Affected in Retinitis Pigmentosa. J Ophthalmol. 2018 Feb 25;2018:3249064. doi: 10.1155/2018/3249064. eCollection 2018. PubMed 29682340 ↗
  • Barbano L, Ziccardi L, Antonelli G, Nicoletti CG, Landi D, Mataluni G, Falsini B, Marfia GA, Centonze D, Parisi V. Multifocal Electroretinogram Photopic Negative Response: A Reliable Paradigm to Detect Localized Retinal Ganglion Cells' Impairment in Retrobulbar Optic Neuritis Due to Multiple Sclerosis as a Model of Retinal Neurodegeneration. Diagnostics (Basel). 2022 May 6;12(5):1156. doi: 10.3390/diagnostics12051156. PubMed 35626311 ↗
  • Parisi V, Ziccardi L, Stifano G, Montrone L, Gallinaro G, Falsini B. Impact of regional retinal responses on cortical visually evoked responses: multifocal ERGs and VEPs in the retinitis pigmentosa model. Clin Neurophysiol. 2010 Mar;121(3):380-5. doi: 10.1016/j.clinph.2009.09.032. Epub 2010 Jan 13. PubMed 20071230 ↗
  • Falsini B, Galli-Resta L, Fadda A, Ziccardi L, Piccardi M, Iarossi G, Resta G. Long-term decline of central cone function in retinitis pigmentosa evaluated by focal electroretinogram. Invest Ophthalmol Vis Sci. 2012 Nov 19;53(12):7701-9. doi: 10.1167/iovs.12-11017. PubMed 23111612 ↗
  • Hong Y, Li H, Sun Y, Ji Y. A Review of Complicated Cataract in Retinitis Pigmentosa: Pathogenesis and Cataract Surgery. J Ophthalmol. 2020 Dec 21;2020:6699103. doi: 10.1155/2020/6699103. eCollection 2020. PubMed 33489339 ↗
  • Bakthavatchalam M, Lai FHP, Rong SS, Ng DS, Brelen ME. Treatment of cystoid macular edema secondary to retinitis pigmentosa: a systematic review. Surv Ophthalmol. 2018 May-Jun;63(3):329-339. doi: 10.1016/j.survophthal.2017.09.009. Epub 2017 Oct 5. PubMed 28987613 ↗
  • Olivares-Gonzalez L, Velasco S, Campillo I, Rodrigo R. Retinal Inflammation, Cell Death and Inherited Retinal Dystrophies. Int J Mol Sci. 2021 Feb 20;22(4):2096. doi: 10.3390/ijms22042096. PubMed 33672611 ↗
  • Georgiou M, Robson AG, Fujinami K, de Guimaraes TAC, Fujinami-Yokokawa Y, Daich Varela M, Pontikos N, Kalitzeos A, Mahroo OA, Webster AR, Michaelides M. Phenotyping and genotyping inherited retinal diseases: Molecular genetics, clinical and imaging features, and therapeutics of macular dystrophies, cone and cone-rod dystrophies, rod-cone dystrophies, Leber congenital amaurosis, and cone dysfunction syndromes. Prog Retin Eye Res. 2024 May;100:101244. doi: 10.1016/j.preteyeres.2024.101244. Epub 2024 Jan 24. PubMed 38278208 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — The individual participant data (IPD) that will be eventually shared are retinal morpho-functional evaluation of patients affected by inherited retinal dystrophies (OCT; OCT-A, mfERG, mfPhNR data), visual field, visual acuity, ocular complications related to IRDs.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2025 to primary completion in Dec 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 18, 2026
StartActual
Dec 10, 2025
Primary completionActual
Dec 10, 2025
CompletionEst.
Oct 21, 2036
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944170
Lead sponsor
Fondazione G.B. Bietti, IRCCS
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Dec 10, 2025
Primary completion
Dec 10, 2025
Completion
Oct 21, 2036 (estimated)
Last update
Nov 18, 2026

Study contacts

Lucia Ziccardi, Professor
Contact
lucia.ziccardi@fondazionebietti.it
+39 0684009486
Vincenzo Parisi, Professor
Contact
vincenzo.parisi@fondazionebietti.it
+39 0684009486
Lucia Ziccardi, Professor
principal investigator · IRCCS Fondazione G. B. Bietti

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion